How can healthcare professionals contribute to generate data on behavioural changes?

Jamie Wilkinson MSc, PGCert, MPharm(Hons), Dip HE, FRSPH, MRPharmS, PFPH

Director of Professional Affairs, Pharmaceutical Group of the European Union (PGEU) Member, EMA Healthcare Professionals Working Party (HCPWP) Co-chair, EMA HCPWP Risk Minimisation Measures (RMM) Topic Group (TG)

Background

EMA's Healthcare Professionals' Working Party (HCP WP) Topic Group on Risk Minimisation Measures (RMM TG), Oct 2015 - Present

Scope of this presentation Share some of the learnings from the TG and implications for regulators and HCPs

Creation of the RMM TG

Conclusions from the Sept 2015 EMA Workshop on RMMs

Optimise use of current regulatory tools

Collaboration with HCPs & patients is key to developing RMMs

Understand factors that affect adherence to RMMs by patients & HCPs

Effective communication

A more systematic approach to measuring the effectiveness of RMMs at different levels

Collaboration with HCPs & patients

Pts & HCPs should be involved early in design:

- both to optimise existing and develop new RMMs
- as much can be learnt from those with real-life experience of implementation of RMMs, e.g. nurses, pharmacists.

Engagement:

- can take place through the existing frameworks of EMA's working parties
- as well as through new interactions with other organisations and individuals.

HCP WP RMM "Topic Group" (TG)

- Created along side several other thematic TGs end of 2015
- Objectives
 - Discuss current practices/experience in development/implementation of RMMs
 - Brainstorm how to facilitate input from HCPs into the feasibility, information and evaluation of RMMs; product-specific issues, therapeutic class and overall therapeutic environment
 - Discuss how to better inform HCPs on ongoing activities/initiatives in the EU regulatory network for post-authorisations and prepare recommendations as appropriate.
 - Survey of HCP WP on 4 recent RMMs
 - Analysis & recommendations ready
- Next steps....

Understand factors that affect adherence to RMMs

To avoid unnecessary burden, regulators need to ensure that risk minimisation measures are:

Well balanced

• Feasible

Consideration should also be given to unintended consequences of a measure:

 E.g. lack of safer alternatives when restricting access to a critical medicine

HCP WP RMM "Topic Group" (TG)

- Created along side several other thematic TGs end of 2015
- Objectives
 - Discuss current practices/experience in development/implementation of RMMs
 - Brainstorm how to facilitate input from HCPs into the feasibility, information and evaluation of RMMs; product-specific issues, therapeutic class and overall therapeutic environment
 - Discuss how to better inform HCPs on ongoing activities/initiatives in the EU regulatory network for post-authorisations and prepare recommendations as appropriate.
- Survey of HCP WP on 4 recent RMMs
- Analysis currently underway
- Next steps....

Understand factors that affect adherence to RMMs



A strong network and communication channels that allow healthcare professionals to engage with patients and regulators needs to be in place.



Regulators need to engage further with stakeholders and more is to be done to create an atmosphere of risk awareness without undermining trust. HCP WP RMM "Topic Group" (TG)

(As previously described)

Impact of Pharmacovigilance PRAC <u>Strategy</u>² This <u>Workshop</u>³

PRAC strategy has identified four key areas of focus:

- 1. Effectiveness of risk minimisation actions
- 2. Effectiveness of specific pharmacovigilance processes
- 3. Enablers of effective pharmacovigilance including stakeholder trust and engagement
- 4. Method identification and development

Overview of Survey



HCPs (primary & secondary care, specialist & generalist) completed questionnaire over summer 2016



Implementation and adherence to RMMs in practice – what works well and what are the barriers?



Tailored (for each RMM), structured, closed questionnaire with open space for comments to elaborate / give practice experience



Valproate, high strength insulin, bisphosphonates/denosumab & fentanyl patches

Challenges - Questions

Optimisation of existing RMMs and development of new RMMs

Balance & proportionality

Feasibility

Unintended consequences of an RMM

Challenges - Answers

Space on packaging for pharmacy labels?

Packaging needs to be clearly designed for all users (e.g. colour blind / visually impaired insulin users) and to prompt HCPs in counselling

If a medication is available in multiple strengths, there is always a risk?

> DHCPs - Lost in the post? Surgery? Ward? Pharmacy?

Delay between launch of RMM and regular use of medication

Challenges - Answers

Information overload (checklists, cards, communications from all areas)

Set number of "information materials" per pack used for multiple patients

Vague checklists – not diagnosis / condition specific

> Not all HCPs have access to diagnoses / indications

Health system hierarchy & reporting

Opportunities - Questions

Learnings from those with real-life experience implementing RMMs, e.g. nurses, pharmacists

New tools allow instant access to online information Ensuring correct media & correct tool used for each situation

Message adapted to each audience

Opportunities - Answers

Involve HCPs earlier on in the development process

Guides should cover all HCPs involved in medication use

Target communications with appropriate tool and to appropriate audience, using mixed media

Use of scientific publications / communications / events

Opportunities - Answers

Integration into Institutional protocols / guidelines


> Access to shared eHealth records (with indications / diagnoses)

Multi-professional collaboration & shared responsibilities

*Continuing Education / Continuous Professional Development

Some Practice-based Solutions

(from professional organisations)



Communication from EU-Level Organisations?

References

¹http://www.ema.europa.eu/ema/index.jsp?curl=pages/news and events/events/2015/08/event detail 001193.jsp&mid=WC0b01ac058004d5c3 ²http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/01/WC500199756.pdf ³ http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC500204177.pdf ⁴ http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2016/07/event_detail_001311.jsp&mid=WC0b01ac058004d5c3 ⁵ http://www.ema.europa.eu/ema/index.jsp?curl=pages/news and events/events/2016/08/event detail 001316.jsp&mid=WC0b01ac058004d5c3 ⁶http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mid=WC0b01ac0580961211 ⁷http://www.portalfarma.com/Profesionales/consejoinforma/Paginas/Buenas-practicas-Farmacia-Comunitaria.aspx ⁸https://www.researchgate.net/publication/278716124_Pharmacotherapeutic_Circles ⁹https://www.medicijngebruik.nl/english/products-and-services ¹⁰http://aop.sagepub.com/content/40/9/1640.abstract ¹¹http://www.ordre.pharmacien.fr/Le-Dossier-Pharmaceutique/Qu-est-ce-que-le-DP ¹²http://www.apb.be/fr/corp/Le-pharmacien/role-et-taches-principales/Pages/Dossier-pharmaceutique-partage.aspx ¹³https://www.gov.uk/government/publications/toolkit-on-the-risks-of-valproate-medicines-in-female-patients ¹⁴https://www.gov.uk/government/publications/e-learning-modules-medicines-and-medical-devices/e-learning-modules-medicines-and-medical-devices ¹⁵http://pro.medicin.dk/Generelt/Patientsikkerhed ¹⁶http://www.rpharms.com/science-and-research/research-ready.asp